Hormonal manipulations and breast cancer

Obstetrical and Gynecological Survey

Volumn 57, Issue 5, 2002, Pages 314-323

  Benshushan, Abraham ^a,b   Brzezinski, Amnon ^a  

^a HEBREW UNIVERSITY   (Israel)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; BENZOPYRAN DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; CENTCHROMAN; CLOMIFENE; CONTRACEPTIVE AGENT; DROLOXIFENE; EXEMESTANE; FLAVONOID; FORMESTANE; GENISTEIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; HORMONE; HORMONE ANTAGONIST; IDOXIFENE; ISOFLAVONE; LETROZOLE; MELATONIN; PHYTOESTROGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; UNINDEXED DRUG; VOROZOLE;

BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CAUSE OF DEATH; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; NON PROFIT ORGANIZATION; NORTH AMERICA; REVIEW; WESTERN EUROPE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGENS; ESTROGENS, NON-STEROIDAL; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONE REPLACEMENT THERAPY; HUMANS; ISOFLAVONES; MELATONIN; PHYTOESTROGENS; PLANT PREPARATIONS; RECEPTORS, ESTROGEN;

EID: 0036253725     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006254-200205000-00024     Document Type: Review

References (93)

1. Favorable and unfavorable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomized trials
2. Characteristics that predict breast cancer before and after the menopause
3. Oral contraceptives and breast cancer: Final report of an epidemiological study
4. Review. Oral contraceptives and menopausal estrogens in relation to breast neoplasia
5. Oral contraceptives and breast disease
6. Reproductive factors and breast cancerr
7. In vitro analysis of the cellular proliferative response to 17 β-estradiol of human breast cancer
8. Association of carcinoma of the breast and corpus uteri
9. Menopause and breast cancer risk
10. Relation of estrogen receptor expression to clonal growth and antiestrogen effects on human breast cancer cells
11. Carcinoma of the breast in transsexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics
12. A pospective study of endogenous estrogens and breast cancer in postmenopausal women
13. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey
14. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women
15. Progestins and breast cancer: An epidemiologic review
16. The effect of age and menstrual cycle upon proliferative activity of the normal human breast
17. Oral contraceptive use influences resting breast proliferation
18. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk
19. Breast cancer and the estrogen window hypothesis
20. Reproductive variables and breast cancer risk: A case-control study carried out in campinas, Sao Paulo
21. Estrogen receptor-beta: A novel mediator of estrogen action in brain and reproductive tissues
22. Menopausal estrogen replacement therapy and breat cancer
23. WHO collaborative study on neoplasia and steroid contraception
24. Cancer and Steroid Hormones Study. Oral contraceptive use and the risk of breast cancer
25. Breast cancer and hormonal contraceptives, collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies
26. Breast Cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
27. Hormone replacement therapy and the risk of breast cancer with a favorable histology
28. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer
29. Inhibition of growth by chemical compounds
30. Breast carcinoma associated with pregnancy: A clinician dilemma
31. Survival of breast cancer patients after subsequent term pregnancy: "Healthy mother effect"
32. How subsequent pregnancy affects outcome in women with prior breast cancer
33. Effects of tamoxifen on spinal bone density in women with breast cancer
34. Ovulation induction in in vitro fertilization
35. Hormone replacement therapy and breast cancer
36. The risk of breast cancer after estrogen and estrogen progestin replacement
37. Hormone replacement therapy in previously treated breast cancer patients
38. Hormone replacement therapy in breast cancer
39. Hormone replacement therapy after breast cancer: A review
40. Selective oestrogen receptor modulation: Molecular pharmacology for the millennium
41. Selective estrogen receptor modulators: An alternative to hormone replacement therapy
42. Effects of raloxifene on bone mineral density, serum cholesterol concentration, and uterine endometrium in postmenopausal women
43. Effects of raloxifene on serum lipids and coagulation factors in healthy posmenopausal women
44. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial. Multiple outcomes of raloxifene evaluation
45. Phytoestrogens. The "natural" selective estrogen receptors modulators
46. Nonmalignant conditions of the breast
47. An overview of clinical cancer chemoprevention studies with emphasis on positive phase III studies
48. Genistein inhibition of the growth of human breast cancer cell-independence from estrogen receptors and the multidrug resistance gene
49. Dietary phytoestrogens and the menopause in Japan
50. Phytoestrogen interaction with estrogen receptors in human breast cancer cells
51. Risk factors for breast cancer in women with proliferative breast disease
52. Genistein, a specific inhibitor of tyrosine-specific protein kinases
53. Inhibitory effects of the kinase inhibitor genistein on mammalian DNA topoisomerase II
54. Inhibition of tyrosine protein kinase activity by synthetic isoflavones and flavones
55. The nuclear matrix from rat liver is capable of phosphorylating exogenous tyrosine-containing substance
56. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor
57. Cancer chemoprevention agent development strategies for genistein
58. A review of the clinical effects of phytoestrogens
59. Effect of genistein on topoisomerase activity and on the growth of [val 12]Ha-rastransformed NIH 3T3 cells
60. Mechanisms of action in NIH-3T3 cells of genistein, an inhibitor of EGF receptor tyrosine kinase activity
61. Immunocytochemicall detection of estrogen-regulated antigens in phytoestrogen -treated human breast cancer cells growth as three dimensional cultures in matrigel
62. Molecular effects of genistein on estrogen receptor mediated pathways
63. Antiproliferative activity of mammalian lignan derivatives against the human breast carcinoma cell line, ZR-75-1
64. In vitro hormonal effects of soybean isoflavones
65. Risks versus benefits in the clinical application of aromatase inhibitors
66. Steroidal aromatase inhibitors in elderly patients
67. Melatonin in humans
68. Melatonin and mammary pathological growth
69. Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat
70. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer
71. Melatonin modulates growth factor activity in MCF-7 human breast cancer cells
72. Effect of the pineal hormone melatonin on the proliferation and morphological chracteristics of human breast cancer cells (MCF7) in culture
73. Effects of melatonin on the proliferation of human breast epithelial cells in primary culture
74. Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells
75. The immunoendocrine role of melatonin
76. The role of the neurohormone melatonin as a buffer against macromolecular oxidative damage
77. Increased survival time in brain glioblastomas by a radioendocrine stategy with radiotherapy plus melatonin compared to radiotherapy alone
78. Modulation of cancer endocrine therapy by melatonin: A phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone
79. Follicular stimulation for high tech pregancies: Are we playing it safe?
80. Ovulation and ovarian cancer
81. The risk of ovarian cancer after treatment for infertility
82. Follicular stimulation and ovarian cancer?
83. Ovarian tumors in a cohort of infertile women
84. Ovarian stimulation and breast cancer: Is there a link?
85. Breast and ovarian cancer incidence after infertility and in vitro fertilization
86. Risk of breast cancer in a cohort of infertile women
87. Treatment with human chorionic gonadotropin and risk of breast cancer
88. Fertility treatment and risk of breast cancer
89. Prevention of rat mammary carcinoma utilizing leuprolide as an equivalent to oophorectomy
90. The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary